Calyxo closes $50M funding round to support kidney stone treatment

Calyxo announced that it closed a $50 million Series D financing round to support its CVAC aspiration system for kidney stone removal.

Avidity Partners led the round, with existing investors Questa Capital and CRG providing significant participation.

Pleasanton, California–based Calyxo’s CVAC system uses irrigation and aspiration to remove kidney stones. The design aims to minimize residual stone burden. CVAC has already been used to successfully treat more than 1,300 patients in the U.S.

The latest round of funding adds to the $32.7 million raised in a Series C round last year.

“We are excited about this round of funding which will further accelerate the company’s momentum,” said Calyxo president & CEO Joe Catanese. “Despite the challenging market conditions, we received strong support from investors who believe in our team, our mission and the promise of our CVAC technology. Our kidney stone treatment innovations will improve care for …

Read more
  • 0

Calyxo raises $32.7M for kidney stone treatment

Kidney stone removal technology developer Calyxo announced today that it closed a $32.7 million Series C financing round.

Pleasanton, California-based Calyxo develops the CVAC Aspiration system designed to use irrigation and aspiration to remove kidney stones with the goal of a surgically stone-free outcome.

According to a news release, Questa Capital and CRG led the Series C funding round completed today.

“We are excited to be moving into the next step of our evolution,” Calyxo President and CEO, Joe Catanese said in the release. “Kidney stone disease is a painful problem for patients, and it consumes vast amounts of healthcare resources each year. We believe our solutions will better meet the needs of kidney stone patients and transform the care of this condition. We look forward to applying this latest financing round toward further product development and the expansion of our team.”

Catanese previously co-founded NeoTract, which developed the …

Read more
  • 0